In today’s recent session, 8.66 million shares of the Silexion Therapeutics Corp (NASDAQ:SLXN) have been traded, and its beta is 0.05. Most recently the company’s share price was $0.92, and it changed around $0.11 or 13.22% from the last close, which brings the market valuation of the company to $7.97M. SLXN at last check was trading at a discount to its 52-week high of $122.02, offering almost -13163.04% off that amount. The share price’s 52-week low was $0.57, which indicates that the recent value has risen by an impressive 38.04% since then. We note from Silexion Therapeutics Corp’s average daily trading volume that its 10-day average is 99590.0 shares, with the 3-month average coming to 1.64 million.
Silexion Therapeutics Corp stock received a consensus recommendation rating of Overweight, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended SLXN as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight.
Silexion Therapeutics Corp (NASDAQ:SLXN) trade information
Instantly SLXN has been showing a green trend so far today with a performance of 13.22% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 0.9853 on recent trading dayincreased the stock’s daily price by 6.63%. The company’s shares are currently down -99.10% year-to-date, but still up 14.31% over the last five days. On the other hand, Silexion Therapeutics Corp (NASDAQ:SLXN) is -3.03% down in the 30-day period. We can see from the shorts that 0.32 million shares have been sold at a short interest cover period of 0.29 day(s).
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -286.10%. Silexion Therapeutics Corp earnings are expected to increase by 96.51% in 2025, but the outlook is positive 63.05% per year for the next five years.
SLXN Dividends
Silexion Therapeutics Corp’s next quarterly earnings report is expected to be released on 2025-May-13.
Silexion Therapeutics Corp (NASDAQ:SLXN)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 6.06% of Silexion Therapeutics Corp shares, and 10.41% of them are in the hands of institutional investors. The stock currently has a share float of 11.08%.
The former held 587.0 shares worth $570.0, making up 0.03% of all outstanding shares.
